Fareed M, Suri K, Qureshi Adnan I
Zeenat Qureshi Stroke Research Center, Departments of Neurology, University of Minnesota, MN, USA, and Hennepin County Medical Center, Minneapolis, MN, USA.
J Vasc Interv Neurol. 2012 Jun;5(1):27-32.
While results of clinical trials are used to impact practice among patients with ischemic stroke, very little information is available regarding proportion and characteristics of patients recruited in clinical trials in general practice.
We performed this analysis to provide an audit of recruitment in clinical trials among patients with acute ischemic stroke using data from the University Healthsystems Consortium benchmarking project. A review of 40 consecutive ischemic stroke cases meeting inclusion criteria and discharge within a 6-month period was conducted in 32 hospitals.
A total of 1256 patients (mean age 67 years, range 18--99 years) were included. A total of 77 (6%) patients were recruited in clinical trials; 33 and 14 patients recruited in drug or device trials, respectively. In the multivariate analysis, age under 80 years (odd ratio [OR] 2.2, 95% confidence interval [CI] 1.0--4.9), white or African-American race as compared with others (OR 2.5, 95% CI 0.98--6.6), evaluation by a neurologist or stroke team (OR 14.8, 95% CI 2.0--108), the use of intravenous thrombolysis (OR 8.4, 95% CI 4.9--14.4), and history of hypertension (OR 1.9, 95% CI 1.0--3.4) were associated with recruitment in clinical trials. There was no relationship between patient's gender and recruitment in clinical trials. The rate of intracranial hemorrhage (6% vs 2%, p<0.05) and progression of stroke (12% vs 3%, p<0.05) were higher among those recruited in clinical trials.
Patients recruited in clinical trials appear to have different characteristics from those who are not recruited limiting the generalizability of results from current trials.
虽然临床试验结果被用于影响缺血性中风患者的治疗实践,但关于在全科医疗中招募到临床试验中的患者比例及特征的信息却非常少。
我们利用大学卫生系统联盟基准项目的数据进行了此项分析,以审核急性缺血性中风患者临床试验的招募情况。在32家医院对连续40例符合纳入标准并在6个月内出院的缺血性中风病例进行了回顾。
共纳入1256例患者(平均年龄67岁,范围18 - 99岁)。共有77例(6%)患者被招募到临床试验中;分别有33例和14例患者被招募到药物或器械试验中。在多变量分析中,80岁以下(比值比[OR] 2.2,95%置信区间[CI] 1.0 - 4.9)、白种人或非裔美国人相较于其他种族(OR 2.5,95% CI 0.98 - 6.6)、由神经科医生或中风团队评估(OR 14.8,95% CI 2.0 - 108)、使用静脉溶栓治疗(OR 8.4,95% CI 4.9 - 14.4)以及有高血压病史(OR 1.9,95% CI 1.0 - 3.4)与被招募到临床试验相关。患者性别与被招募到临床试验之间无关联。在临床试验招募的患者中,颅内出血发生率(6% 对 2%,p<0.05)和中风进展率(12% 对 3%,p<0.05)更高。
被招募到临床试验中的患者似乎与未被招募的患者具有不同特征,这限制了当前试验结果的可推广性。